AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

783.163

-9.888-1.25%

Number of Gainers:8

Number of Losers:22

Number of Flat:16

PE:- -

High:793.095

Open:793.093

Low:782.162

Close:793.051

Loading ...

ASX Midday Sector Update: Healthcare Sector Jumps, Information Technology Stocks Struggle

MT Newswires Live

Botanix Pharmaceuticals Seeks AU$40 Million via Institutional Placement; Shares Rise 10%

MT Newswires Live

Morgan Stanley’s top-ranked ASX healthcare picks for right now

3 ASX Penny Stocks With Market Caps Under A$2B

Simply Wall St.

BRIEF-Botanix Pharmaceuticals Says Received Firm Commitments For A$40 Million

Botanix Pharmaceuticals - Received Firm Commitments for a$40 Mln Capital Raising at Issue Price of a$0.33 per Share

THOMSON REUTERS

Botanix Pharmaceuticals Ltd-Proposed Issue of Securities - BOT

THOMSON REUTERS

ASX Small-Cap Stocks to Watch

MT Newswires Live

Is the CSL share price a buy? Here's a top broker's view

ASX Growth Stocks With Strong Insider Backing

Simply Wall St.

High Growth Tech Stocks To Watch In April 2025

Simply Wall St.

How I'd invest in ASX 200 shares if I wanted to sleep well during market volatility

Here are the top 10 ASX 200 shares today

Australian Shares Rise Amidst Temporary Reprieve for Electronic Tariffs; EBR Systems Receives US FDA Approval for Heart Failure Treatment Device

MT Newswires Live

BUZZ-Australian healthcare stocks rise as Bell Potter sees most cos unfazed by potential tariffs

Monash IVF May Take Some Time to Recover From Mix-Up -- Market Talk

FDA OK for Neuren’s first ever Phase 3 trial in children with Phelan-McDermid syndrome

The Market Herald

Monday’s HotCopper Trends: Invictus exploration, Neuren’s FDA tick | April 14, 2025

The Market Herald

Why DroneShield, Fiducian, Neuren, and Newmont shares are storming higher

BUZZ-Australia's Neuren Pharmaceuticals rises on FDA trial update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":783.16254,"timestamp":1745301599986,"preClose":793.05054,"halted":0,"volume":66212972,"delay":0,"changeRate":-0.012468,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-9.888,"latestTime":"04-22 16:00:00 AEST","open":793.0932,"high":793.0951,"low":782.16187,"amount":297259232,"amplitude":0.013786,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1745280000000,1745301600000]],"turnoverRate":0.001795,"increases":7,"decrements":20,"flats":16,"marketCap":123703500651.625,"floatMarketCap":121201824994.75},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":793.0951,"amplitude":0.013786,"preClose":793.05054,"low":782.16187,"latestPrice":783.16254,"volume":66212972,"delay":0,"open":793.0932,"prevYearClose":936.801,"prevWeekClose":793.051,"prevMonthClose":815.605,"prevQuarterClose":815.605,"fiveDayClose":769.762,"twentyDayClose":833.755,"sixtyDayClose":904.08,"secType":"PLATE","market":"AU","turnoverRate":0.001795,"marketCap":123703500651.625,"floatMarketCap":121201824994.75,"timestamp":1745301599986,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":8,"down":22,"flat":16},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527048658","title":"ASX Midday Sector Update: Healthcare Sector Jumps, Information Technology Stocks Struggle","url":"https://stock-news.laohu8.com/highlight/detail?id=2527048658","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527048658?lang=en_us&edition=fundamental","pubTime":"2025-04-15 11:36","pubTimestamp":1744688210,"startTime":"0","endTime":"0","summary":"The healthcare sector climbed 1.11% at midday Tuesday.Stocks rallied after some volatility on Wall Street, with investors cautiously optimistic after a temporary pause on tariffs on some electronic devices. The S&P 500 closed up 2.2%.Botanix Pharmaceuticals  received firm commitments to raise AU$40 million via a non-underwritten institutional placement, its shares rose 9% in midday trade.On the flip side, the information technology stocks fell, shedding 0.45%.EROAD  does not expect any material impact of the US' 10% blanket tariffs on its revenue or earnings, generating 44% of its revenue from the US market, with roughly 88% being from services not subject to the US import tariffs. It produces most of its hardware products through manufacturers in Indonesia, the Philippines, and Vietnam.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ERD.AU","HCSG","BK7084","BOT.AU","BK7139","BK4134","BK7508","III","BK7502","BK4137","BOQ.AU","BK7096"],"gpt_icon":0},{"id":"2527110765","title":"Botanix Pharmaceuticals Seeks AU$40 Million via Institutional Placement; Shares Rise 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527110765","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527110765?lang=en_us&edition=fundamental","pubTime":"2025-04-15 10:56","pubTimestamp":1744685780,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals (ASX:BOT) received firm commitments to raise AU$40 million via a non-underwritten institutional placement, according to a Tuesday filing with the Australian bourse.The placemen","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BOT.AU","BK7508","BK7502"],"gpt_icon":0},{"id":"2527107074","title":"Morgan Stanley’s top-ranked ASX healthcare picks for right now","url":"https://stock-news.laohu8.com/highlight/detail?id=2527107074","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527107074?lang=en_us&edition=fundamental","pubTime":"2025-04-15 10:46","pubTimestamp":1744685174,"startTime":"0","endTime":"0","summary":"Despite the latest noises out of the White House promising some tariff respite, Trump’s ongoing trade war remains the big spectre looming over markets.According to research from Morgan Stanley, one sector that could weather the storm is healthcare, especially if the worst were to happen and we entered a period of stagflation or even recession.Here are its two big-name stock picks and the reasons it thinks the sector is well-positioned right now.While pharmaceuticals are currently exempt from US tariffs, Trump hinted that an announcement on specific pharma tariffs could be expected “soon”.Regardless, Morgan Stanley believes leading ASX health stocks should be able to offset any tariff impact through minimal price increases.Using the GFC as an instructive case study, Morgan Stanley reviewed the performance of the healthcare industry against the ASX 200during that time in case we entered a similar period of lower growth, higher inflation and more unemployment.According to Morgan Stanley's","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/morgan-stanley-s-top-ranked-asx-healthcare-picks-for-right-now","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/morgan-stanley-s-top-ranked-asx-healthcare-picks-for-right-now","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["LU2347655156.SGD","LU2133065610.SGD","LU1363072403.SGD","LU1989772923.USD","LU0098860793.USD","BK7007","LU2357305700.SGD","MS","LU0006306889.USD","LU0106831901.USD","LU0225283273.USD","LU0795875086.SGD","BK4504","BK7508","LU2271345857.HKD","LU0912757837.SGD","BK7067","IE00BKVL7J92.USD","LU1720051108.HKD","LU0971096721.USD","LU0314104364.USD","BK4581","CSL.AU","RMD.AU","BK4516","BK7501","BK4585","LU0795875169.SGD","LU2028103732.USD","LU0158827948.USD","LU1720051017.SGD","LU1548497426.USD","IE00BZ1G4Q59.USD","LU1732800096.USD","LU2089284900.SGD","LU0106261372.USD","BK7511","LU0158827781.USD","LU1668664300.SGD","BK4588","LU2023251221.USD","LU2111349929.HKD","LU2089283258.USD","LU1989772840.SGD","LU1162221912.USD","LU0320765646.SGD","BK4127","LU1732799900.SGD","LU0267386448.USD","LU1074936037.SGD"],"gpt_icon":0},{"id":"2527464907","title":"3 ASX Penny Stocks With Market Caps Under A$2B","url":"https://stock-news.laohu8.com/highlight/detail?id=2527464907","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527464907?lang=en_us&edition=fundamental","pubTime":"2025-04-15 10:04","pubTimestamp":1744682695,"startTime":"0","endTime":"0","summary":"As Australian shares continue their hopeful uptrend, buoyed by positive developments in global markets and a green jump on the Oz bourse, investors are exploring diverse opportunities. Penny stocks, often representing smaller or newer companies, remain an intriguing area for those looking to venture beyond the big names. While the term may seem outdated, these stocks still offer potential for growth when backed by strong financials and a clear trajectory.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-pnv/polynovo-shares/news/3-asx-penny-stocks-with-market-caps-under-a2b-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7016","BK7088","PNV.AU","BK7021","BIS.AU","BK7126","RPL.AU","BK7508","CLX.AU","BK7045","BK7048","SXE.AU","EZZ.AU","BOE.AU","IGL.AU","BK7058","BK7055","BK7083","GTN.AU","BK7062","BRN.AU","NWH.AU","AX1.AU","BK7129","LBL.AU"],"gpt_icon":0},{"id":"2527778741","title":"BRIEF-Botanix Pharmaceuticals Says Received Firm Commitments For A$40 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2527778741","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527778741?lang=en_us&edition=fundamental","pubTime":"2025-04-15 09:24","pubTimestamp":1744680299,"startTime":"0","endTime":"0","summary":"BRIEF-Botanix Pharmaceuticals Says Received Firm Commitments For A$40 Million April 15 (Reuters) - Botanix Pharmaceuticals BOT.AX:RECEIVED FIRM COMMITMENTS FOR A$40 MILLION CAPITAL RAISING AT ISSUE PRICE OF A$0.33 PER SHAREFurther company coverage: BOT.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QS1Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOT.AU","BK7096","BK7508","BK7502"],"gpt_icon":0},{"id":"2527120923","title":"Botanix Pharmaceuticals - Received Firm Commitments for a$40 Mln Capital Raising at Issue Price of a$0.33 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2527120923","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527120923?lang=en_us&edition=fundamental","pubTime":"2025-04-15 07:51","pubTimestamp":1744674712,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nFWN3QS1Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7502","BOT.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2527209261","title":"Botanix Pharmaceuticals Ltd-Proposed Issue of Securities - BOT","url":"https://stock-news.laohu8.com/highlight/detail?id=2527209261","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527209261?lang=en_us&edition=fundamental","pubTime":"2025-04-15 07:51","pubTimestamp":1744674664,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nTUE4JFGYT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7502","BK7096","BOT.AU","BK7508"],"gpt_icon":0},{"id":"2527912710","title":"ASX Small-Cap Stocks to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2527912710","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527912710?lang=en_us&edition=fundamental","pubTime":"2025-04-15 07:42","pubTimestamp":1744674140,"startTime":"0","endTime":"0","summary":"Investors are likely to keep an eye on the following small-cap stocks listed on the Australian Securities Exchange.Noxopharm Noxopharm passed its final in vivo preclinical safety study for its SOF-SKN drug candidate for autoimmune diseases, with no issues identified, ahead of regulatory submission for the Heracles clinical trial.Great Western Exploration Great Western Exploration completed its maiden drilling program at the Sumo niobium target, located within its Yerrida North project in Western Australia.Swift Networks Group Swift Networks Group extended the closing date of its entitlement offer by two weeks to May 6, following \"significant\" global stock market volatility and shareholder requests. The extension allows additional time to receive the entitlement offer material and evaluate the opportunity.Rincon Resources Rincon Resources completed a site visit to its Laverton gold project in Western Australia and is now preparing for its first drilling on-ground since 2021.Aurumin Auru","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","BK7508","RCR.AU","BK7067","BK7501","SW1.AU","XJO.AU","BK7104","BK7035","GTE.AU","XAO.AU","XKO.AU","NOX.AU","AUN.AU"],"gpt_icon":0},{"id":"2527109122","title":"Is the CSL share price a buy? Here's a top broker's view","url":"https://stock-news.laohu8.com/highlight/detail?id=2527109122","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527109122?lang=en_us&edition=fundamental","pubTime":"2025-04-15 06:47","pubTimestamp":1744670841,"startTime":"0","endTime":"0","summary":"The CSL Ltd (ASX: CSL) share price is down 15% since the start of 2025 and 20% in the last six months, as the chart below shows. After a sizeable decline, interested investors may be wondering whether","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/15/is-the-csl-share-price-a-buy-heres-a-top-brokers-view/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CSL.AU","SG9999004303.SGD","BK4086","LU1169589451.USD","SGXZ23171101.USD","BK7511","LU1169590202.USD","BK7501","BK7067","CSL","BK7508","LU0728928796.USD"],"gpt_icon":0},{"id":"2527072145","title":"ASX Growth Stocks With Strong Insider Backing","url":"https://stock-news.laohu8.com/highlight/detail?id=2527072145","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527072145?lang=en_us&edition=fundamental","pubTime":"2025-04-15 03:38","pubTimestamp":1744659487,"startTime":"0","endTime":"0","summary":"Amidst a positive trading session on the Australian market, with sectors like IT and Materials leading gains, investors are keenly observing growth companies that demonstrate strong insider ownership. In the current climate, where confidence is bolstered by robust performances in both local and international markets, stocks with significant insider backing can be appealing due to their potential for aligned interests and long-term commitment from those who know the business best.Top 10 Growth Companies With High Insider Ownership In Australia. Click here to see the full list of 94 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.Dropsuite is experiencing significant earnings growth, forecasted at 33.8% annually, outpacing the Australian market. However, its net profit margin has declined from 5.2% to 2%. Recent developments include a definitive agreement for acquisition by NinjaOne Australia Pty Ltd for A$414.53 million, pending shareholder approval on Ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/asx-growth-stocks-strong-insider-193807336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7126","BK7095","BK7007","BK7016","BBT.AU","BK7096","ACR.AU","XJO.AU","BK7077","CYC.AU","NAN.AU","TTT.AU","AAL.AU","IMA.AU","BK7129","BK7036","FEX.AU","NWF.AU","BK7078","BK7116","PLT.AU","BK7153","XKO.AU","BK7093","BK7084","BK7508","DSE.AU","BK7503","KGN.AU","BK7049","XAO.AU","AVA.AU"],"gpt_icon":0},{"id":"2527714507","title":"High Growth Tech Stocks To Watch In April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2527714507","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527714507?lang=en_us&edition=fundamental","pubTime":"2025-04-15 03:35","pubTimestamp":1744659336,"startTime":"0","endTime":"0","summary":"The Australian market showed strength on Monday, with the IT sector leading gains by 2.6%, buoyed by positive momentum from Wall Street and a rise in materials driven by higher iron ore and gold prices. In this environment, identifying high growth tech stocks involves looking for companies that are capitalizing on current market trends and demonstrating resilience during earnings season, as they can potentially offer significant opportunities for investors seeking exposure to innovative sectors.Click here to see the full list of 48 stocks from our ASX High Growth Tech and AI Stocks screener.Overview: Clinuvel Pharmaceuticals Limited is a biopharmaceutical company that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders across Australia, Europe, the United States, Switzerland, and internationally; it has a market cap of A$536.43 million.Operations: Clinuvel Pharmaceuticals generates revenue primarily from its biopharmaceutical sector, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-watch-193536682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7508","CUV.AU","XAO.AU","SDR.AU","BK7067","IFM.AU","BK7016","BK7503","XKO.AU","XJO.AU"],"gpt_icon":0},{"id":"2527713444","title":"How I'd invest in ASX 200 shares if I wanted to sleep well during market volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2527713444","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527713444?lang=en_us&edition=fundamental","pubTime":"2025-04-14 17:33","pubTimestamp":1744623232,"startTime":"0","endTime":"0","summary":"Let's face it — the share market can be a stressful place when prices are falling, headlines are screaming, and your portfolio is flashing red. But the truth is, volatility is part of the investment r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/14/how-id-invest-in-asx-200-shares-if-i-wanted-to-sleep-well-during-market-volatility/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4585","BK7510","BK7082","BK7511","BK7007","COL.AU","BK4550","TLS.AU","FDN","IVV.AU","BK7042","BK7067","BK7508","NDQ.AU","BK7040","BK7099","GMG.AU","BK7501","BK7155","QLTY.AU","CSL.AU","RMD.AU","BK4588"],"gpt_icon":0},{"id":"2527186297","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2527186297","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527186297?lang=en_us&edition=fundamental","pubTime":"2025-04-14 15:01","pubTimestamp":1744614107,"startTime":"0","endTime":"0","summary":"It was a flying start to the trading week for the S&P/ASX 200 Index (ASX: XJO) this Monday. After a rough end to last week, investors came back from the weekend with a spring in their steps. By the ti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/14/here-are-the-top-10-asx-200-shares-today-14-april-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["SMR.AU","BK7067","XJO.AU","BK7504","PME.AU","NEU.AU","PNV.AU","BK7501","BK7129","BK7016","WHC.AU","BK7507","CU6.AU","SDR.AU","BK7083","MSB.AU","BK7096","BK7126","BK7094","BK7062","PNI.AU","BK7095","BK7508","MIN.AU"],"gpt_icon":0},{"id":"2527977273","title":"Australian Shares Rise Amidst Temporary Reprieve for Electronic Tariffs; EBR Systems Receives US FDA Approval for Heart Failure Treatment Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2527977273","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527977273?lang=en_us&edition=fundamental","pubTime":"2025-04-14 14:59","pubTimestamp":1744613994,"startTime":"0","endTime":"0","summary":"Australian shares rose on Monday after US President Trump temporarily exempted China from a 125% tariff on popular electronics and introduced flat 10% tariffs on electronics around the globe.The S&P/A","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK7082","EBR","BK7040","CRT","XJO.AU","WOW.AU","BK4213","BK7501","NEU.AU","BK7511","COL.AU","XAO.AU","XKO.AU","BK4081","BK7508","BK7007","IE00B1B80R65.USD","EBR.AU"],"gpt_icon":0},{"id":"2527978495","title":"BUZZ-Australian healthcare stocks rise as Bell Potter sees most cos unfazed by potential tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2527978495","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527978495?lang=en_us&edition=fundamental","pubTime":"2025-04-14 13:17","pubTimestamp":1744607871,"startTime":"0","endTime":"0","summary":"BUZZ-Australian healthcare stocks rise as Bell Potter sees most cos unfazed by potential tariffs** Index of Australian Healthcare stocks .AXHJ rises 1.9%, tracking broadly positive market sentiment .A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nL4N3QS0C5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","CSL.AU","BK7503","BK7511","NEU.AU","BK7096","PNV.AU","BK7501","NAN.AU","BK7126","TRJ.AU","BK7067","BK7508","ARX.AU"],"gpt_icon":0},{"id":"2527924225","title":"Monash IVF May Take Some Time to Recover From Mix-Up -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2527924225","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527924225?lang=en_us&edition=fundamental","pubTime":"2025-04-14 12:13","pubTimestamp":1744603980,"startTime":"0","endTime":"0","summary":"0413 GMT - Public market sentiment toward Monash IVF could take a long while to improve following the fertility services provider's embryo mix-up at its Brisbane clinic, Jefferies analysts tell clients. Last week, Monash's shares tumbled 36% in a day on news that an embryo was transferred to the wrong patient, resulting in the birth of a child. Warning that sentiment toward Monash to remain weak for some time, the Jefferies analysts mull recent private-equity activity in the IVF space. They tell clients in a note that the historic transaction multiple for IVF assets is 13.8 times Ebitda for the last 12 months. Jefferies keeps a buy rating and A$1.45 target price on the stock, which is up 3.3% at A$0.7125. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7113","MVF.AU","BK7508"],"gpt_icon":0},{"id":"2527268739","title":"FDA OK for Neuren’s first ever Phase 3 trial in children with Phelan-McDermid syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2527268739","media":"The Market Herald","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527268739?lang=en_us&edition=fundamental","pubTime":"2025-04-14 10:11","pubTimestamp":1744596660,"startTime":"0","endTime":"0","summary":"Neuren Pharma  has popped 20% as the FDA greenlights its upcoming Phase 3 trial in children with Phelan-McDermid syndrome  – the first ever to be conducted.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.A rare disorder, PMS ultimately leads to developmental disabilities in children with the condition that acts on chromosomes. The condition can be inherited genetically, but it can also form sporadically on its own.The FDA approval for Neuren’s Phase 3 trial comes on the back of a meeting it held with regulators in the U.S. establishing primary endpoints for the study.In other words: Deciding what milestones the company would put in place to determine whether or not its drug NNZ-2591 is effective in treating PMS. . The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and cons","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/fda-ok-for-neurens-first-ever-phase-3-trial-in-children-with-phelan-mcdermid-syndrome-2025-04-14/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7096","BK7508","NEU.AU"],"gpt_icon":0},{"id":"2527994124","title":"Monday’s HotCopper Trends: Invictus exploration, Neuren’s FDA tick | April 14, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2527994124","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527994124?lang=en_us&edition=fundamental","pubTime":"2025-04-14 10:08","pubTimestamp":1744596480,"startTime":"0","endTime":"0","summary":"The ASX has been up 1% higher at 7,721 points.Invictus Energy  has been among the most watched on HotCopper forums after the company confirmed Musuma-1 as the first high-impact exploration well to be drilled outside the Mukuyu gas-condensate discovery area, targeting a new play type in the Cabora Bassa Basin.Neuren Pharmaceuticals  has also been trending on news the primary endpoints for its Phase 3 pivotal clinical trial of its drug in Phelan-McDermid syndrome have been confirmed in a meeting with the U.S. FDA.And, finally, Bellevue Gold  has revised its full-year production guidance down and scrapped itsfive-year growth planafter “uncharacteristic geological factors” hindered the gold miner’s output in the March quarter.Bellevue Gold was $1.145 before its trading suspension.Join the discussion: See what’s trending right now on HotCopper, Australia’s largest stock forum, and be part of the conversations that move the markets.The material provided in this article is for information onl","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/mondays-hotcopper-trends-invictus-exploration-neurens-fda-tick-april-14-2025-2025-04-14/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["IVZ.AU","NEU.AU","BK7096","BK7142","BK7508","BGL.AU","BK7104"],"gpt_icon":0},{"id":"2527928510","title":"Why DroneShield, Fiducian, Neuren, and Newmont shares are storming higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2527928510","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527928510?lang=en_us&edition=fundamental","pubTime":"2025-04-14 10:00","pubTimestamp":1744596055,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) has followed Wall Street's lead and is pushing higher. At the time of writing, the benchmark index is up 1.1% to 7,728.6 points. Four ASX shares that are rising more th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/14/why-droneshield-fiducian-neuren-and-newmont-shares-are-storming-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["NEU.AU","BK7062","NEM.AU","FID.AU","XJO.AU","BK7104","BK7508","BK7096","BK7115","DRO.AU"],"gpt_icon":0},{"id":"2527917449","title":"BUZZ-Australia's Neuren Pharmaceuticals rises on FDA trial update","url":"https://stock-news.laohu8.com/highlight/detail?id=2527917449","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527917449?lang=en_us&edition=fundamental","pubTime":"2025-04-14 09:01","pubTimestamp":1744592476,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren Pharmaceuticals rises on FDA trial update** Shares of Neuren Pharmaceuticals NEU.AX up 16% at A$10.7, their biggest intraday percentage gain since December 18, 2023** Stock is top gainer in the ASX 200 benchmark index .AXJO, which is up 0.6% ** The drugmaker says primary endpoints for its Phase 3 trial of NNZ-2591 in Phelan-McDermid syndrome , a genetic disorder, confirmed at a meeting with the U.S. Food and Drug Administration** Stock down 26.5% this year, as of last close  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nL4N3QS02C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":128,"code":"91000000","status":"200"}]}}